GLIDAPA 3D 10/100/1000 SR

Description

Dapaflozin 10, Sitagliptin 100 mg & Metformin SR 1000 What is GLIDAPA 3D 10/100/1000 SR? GLIDAPA 3D 10/100/1000 SR is a powerful triple-combination oral anti-diabetic medication formulated with Dapagliflozin (10 mg), Sitagliptin (100 mg), and Metformin SR (1000 mg). It is specifically designed for the management of Type 2 Diabetes Mellitus (T2DM) in patients who require more than one therapeutic agent to achieve optimal blood sugar control. Dapagliflozin belongs to the SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor class. It lowers blood glucose by increasing urinary glucose excretion. Sitagliptin is a DPP-4 (Dipeptidyl Peptidase-4) inhibitor that enhances incretin hormone activity, improving insulin secretion and reducing glucagon levels. Metformin SR (Sustained Release) improves insulin sensitivity, reduces hepatic glucose production, and supports long-term glycemic control. Together, this combination provides a comprehensive approach to blood sugar regulation, reducing the risks of diabetes-related complications while also supporting weight management and cardiovascular health. Uses of GLIDAPA 3D 10/100/1000 SR This medication is primarily prescribed for: Management of Type 2 Diabetes Mellitus in adults not adequately controlled with single or dual therapy. Reduction of blood glucose levels by targeting multiple pathways of glucose regulation. Improvement in insulin sensitivity and reduction of insulin resistance. Weight management support, since dapagliflozin helps reduce body weight. Cardiovascular protection in high-risk patients, as dapagliflozin is known to provide heart and kidney benefits. Prevention of long-term complications of diabetes such as neuropathy, nephropathy, retinopathy, and cardiovascular diseases. Side Effects of GLIDAPA 3D 10/100/1000 SR Like all medicines, GLIDAPA 3D 10/100/1000 SR may cause some side effects. Most are mild and manageable: Common side effects: Urinary tract infections (UTIs) Genital yeast infections Increased urination Headache Mild gastrointestinal issues (nausea, diarrhea, abdominal discomfort) Less common but possible side effects: Low blood sugar (especially if taken with insulin or sulfonylureas) Lactic acidosis (a rare but serious risk with metformin, more likely in kidney dysfunction) Dehydration due to increased urination Pancreatitis (rare, related to sitagliptin use) If any severe reactions occur (difficulty breathing, chest pain, persistent abdominal pain, or signs of ketoacidosis such as nausea, vomiting, confusion, and rapid breathing), medical attention should be sought immediately. Precautions Before Using GLIDAPA 3D 10/100/1000 SR Kidney & Liver Conditions: Not recommended for patients with severe renal impairment or significant liver dysfunction. Cardiac Patients: Use with caution in patients with heart failure or cardiovascular disease. Elderly Patients: Increased risk of dehydration and kidney problems. Pregnancy & Breastfeeding: Should only be used if prescribed by a doctor after weighing risks and benefits. Surgery & Radiological Procedures: Inform your doctor, as metformin may need to be temporarily stopped in certain conditions. Hydration: Patients should drink adequate fluids to reduce the risk of dehydration and urinary infections. Drug Interactions GLIDAPA 3D 10/100/1000 SR may interact with certain medicines, including: Diuretics: May increase the risk of dehydration and kidney problems. Insulin or sulfonylureas: May increase the risk of hypoglycemia. Corticosteroids & thyroid medicines: Can raise blood sugar levels, reducing drug effectiveness. Alcohol: Increases the risk of lactic acidosis with metformin. Other nephrotoxic drugs (NSAIDs, aminoglycosides): May impair kidney function and increase risks. Always inform your healthcare provider about any medications, supplements, or herbal products you are taking. Conclusion GLIDAPA 3D 10/100/1000 SR (Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin SR 1000 mg) is an advanced triple-therapy for Type 2 Diabetes Mellitus, offering a multi-targeted approach to blood sugar management. By combining three proven anti-diabetic agents, it provides superior glycemic control, supports weight reduction, and lowers the risk of long-term complications. This formulation is especially useful for patients who are not adequately controlled with single or dual therapy and require a stronger, comprehensive treatment option.